{"eventGroups":[{"description":"Cisplatin 25 mg/m\\^2 IV Days 1-3; Ifosfamide 1200 mg/m\\^2 IV Days 1-3; Paclitaxel 175 mg/m\\^2 IV Day 1","id":"EG000","otherNumAffected":13,"otherNumAtRisk":30,"seriousNumAffected":3,"seriousNumAtRisk":30,"title":"Cisplatin + Ifosfamide + Paclitaxel"}],"frequencyThreshold":"2","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3 only, no grade 4 events","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 4 only, no grade 3 events","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3 events, no grade 4","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30,"numEvents":5}],"term":"infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"no grade 4 events","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"deep vein thrombosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3, no grade 4 events","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"central venous catheter related thrombosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3, no grade 4 events","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3 event, no grade 4 events","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"hyperglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3 event, no grade 4 events","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"neuropathy motor"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 3 event, no grade 4","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"thrombocytopenia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23,"numEvents":1}],"term":"allergic reaction"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23,"numEvents":2}],"term":"myocarcial ischemia"}],"timeFrame":"Nine years and 6 months"}